Available Technologies
# of Displayed Technologies: 10 / 14
Applied Category Filter (Click To Remove): Small Molecules
Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells.
The Need
Current therapies…
- College: College of Medicine (COM)
- Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
- Licensing Officer: Schultz, Teri
Novel STK1-targeted small molecule "antibiotic resistance breaker" compounds
TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.
In today’s healthcare landscape, increasingly highly pathogenic and multidrug-resistant S. aureus (MDRSA) strains are replacing traditional methicillin-resistant S. aureus (MRSA) in both community and hospital settings.
The Need
The rise of these resilient multi-drug resistant bacteria has …
- College: College of Medicine (COM)
- Inventors: Pancholi, Vijay
- Licensing Officer: Schultz, Teri
Addressing the Treatment Gap in Advanced Liposarcoma
TS-062480 — Novel therapeutic compounds to treat advanced liposarcoma.
Patients diagnosed with advanced liposarcoma (LPS) face a significant treatment challenge, as current chemotherapy approaches exhibit low response rates of only 25%, leading to a dismal overall survival at 5 years, ranging between 20% to 34%.
The Need
Despite extensive efforts, there has been no s…
- College: College of Medicine (COM)
- Inventors: Beane, Joal; Goryunova, Marina; Hadad, Christopher; He, Yiran; Zhu, Hua
- Licensing Officer: Schultz, Teri
Unleashing the Power of Radiotherapy - Enhancing Tumor Oxygenation with Next-Gen Radiosensitizers
TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives of papaverine designed to enhance tumor oxygenization without PDE-related side effects.
Papaverine is an FDA-approved phosphodiesterase 10A (PDE10A) inhibitor and its clinical use is due to these effects on blood pressure and vascular tone. However, it was found to also be a potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been sho…
- College: College of Medicine (COM)
- Inventors: Denko, Nicholas; Benej, Martin; Haines, Ben; Mitton-Fry, Mark
- Licensing Officer: Schultz, Teri
FraB as a drug target and FraB inhibitors as Salmonella-specific narrow-spectrum therapeutics
TS-059635 — & T2014-282 A method to discover narrow-spectrum antibiotics of salmonellosis, as well as small molecule inhibitors of Salmonella FraB and a Salmonella probiotic strain to enhance the efficacy of FraB inhibitors.
Non-typhoidal salmonellosis is one of the most significant food-borne diseases, in the United States and globally. There are no vaccines available for human use to prevent this disease, and only broad-spectrum antibiotics available to treat the disease. However, antibiotic resistance is on the ris…
- College: College of Medicine (COM)
- Inventors: Ahmer, Brian; Boulanger, Erin; Cool, Austin; Gopalan, Venkat; Kovvali, Sai Sravya Varali; Law, Jamison; Lindert, Steffen; Sabag-Daigle, Anice; Sengupta, Anindita; Thirugnanasambantham, Pankajavalli
- Licensing Officer: Schultz, Teri
An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 —
A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
- College: College of Medicine (COM)
- Inventors: Bansal, Shyam; Gumina, Richard
- Licensing Officer: He, Panqing
Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 —
A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
- College: College of Medicine (COM)
- Inventors: Williams, Terence; Lee, Robert
- Licensing Officer: He, Panqing
Inhibition of DGAT for the treatment of cancer
TS-049730 —
Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…
- College: College of Medicine (COM)
- Inventors: Guo, Deliang
- Licensing Officer: He, Panqing
Translational Activators of the Glutamate Transporter EAAT2 to Treat Neurological and Psychiatric Diseases
TS-043938 — Small molecule technology with novel translational activation mechanism.
Glutamate is a major neurotransmitter in the mammalian central nervous system (CNS) and essential for normal brain function including cognition, memory, and learning. However, the extracellular concentration of glutamate must remain below excitotoxic levels (~ 1 μM) to avoid overstimulation of …
- College: College of Medicine (COM)
- Inventors: Lin, Chien-Liang
- Licensing Officer: Schworer, Adam
AR-12 for the Treatment of Leishmaniasis (Protozoa)
TS-041764 — AR-12 is a FDA-IND approved small molecule that has been repurposed to treat leishmaniasis, a parasitic infection.
Leishmaniasis is a protozoal parasitic disease transmitted by sandflies. The disease affects millions of people worldwide. Sandflies carrying the promastigote form of the parasite bite a human host, attracting macrophages to the site of the wound. Promastigotes are then phagocytized by the macroph…
- College: College of Medicine (COM)
- Inventors: Satoskar, Abhay; Ainslie, Kristy; Bachelder, Eric; Gautam, Shalini; Peine, Kevin
- Licensing Officer: Schultz, Teri
